Lopez-Girona Antonia,Filvaroff Ellen,Xu Shuichan,Raymon Heather,Tsuji Toshiya,Hege Kristen Mae
申请号：
NZ62941114
公开号：
NZ629411A
申请日:
2014.04.16
申请国别(地区):
NZ
年份:
2017
代理人:
摘要：
Disclosed herein is the use of an effective amount of a dihydropyrazino-pyrazine represented by structural formula (I) in the manufacture of a medicament for treating or preventing chronic lymphocytic leukemia (CLL), or T-cell prolymphocytic leukemia (T-PLL) characterized by one or more of deletion of all or part of chromosome 11q, loss or mutation of the gene encoding ATM, loss of ATM expression or function, mutation of IgVH, wild type IgVH, wild type p53/ATM, mutation of p53, dysfunctional p53 or Zap-70 positivity, or T-PLL. The preferred dihydropyrazino-pyrazine is 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt, clathrate, solvate, stereoisomer, tautomer or isotopologue thereof.
